Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | OGA | O60502 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 9/20 | 0.46 |
| ▸ | RAB9A | P51151 | 9/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3468828 | 0.90 | DPP4 (0.46) | NR1H2NR1H3MAPTKMT2ANPSR1 | |
| SCHEMBL14046554 | 0.86 | MAPT (0.51) | NR1H2NR1H3MAPTKMT2ANPSR1 | |
| SCHEMBL2712309 | 0.82 | SCN4A (0.58) | NR1H2NR1H3MAPTKMT2ANPSR1 | |
| SCHEMBL14917116 | 0.81 | AR (0.65) | MAPTOGANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14403376 | 0.81 | RAB9A (0.65) | MAPTOGANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3468624 | 0.80 | HRH3 (0.60) | NR1H2NR1H3MAPTKMT2ANPSR1 | |
| SCHEMBL20644407 | 0.79 | RAB9A (0.64) | NR1H2NR1H3MAPTKMT2ANPSR1 | |
| SCHEMBL3468668 | 0.79 | MAPT (0.61) | MAPTKMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3468713 | 0.78 | HRH3 (0.58) | NR1H2NR1H3MAPTKMT2ANPSR1 | |
| SCHEMBL3468671 | 0.78 | RAB9A (0.49) | MAPTOGANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HIGH POINT PHARMACEUTICALS, LLC | 2010-11-25 | — | — | US | claimed |
| US-8772285-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772285-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772285-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | VTVX HOLDINGS II LLC | 2013-03-28 | — | — | US | disclosed |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | VTVX HOLDINGS II LLC | 2013-03-28 | — | — | US | disclosed |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | VTVX HOLDINGS II LLC | 2013-03-28 | — | — | US | disclosed |
| US-8394842-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394842-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394842-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-03-12 | — | — | US | disclosed |
| EP-1999120-B1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2012-06-27 | — | — | EP | disclosed |
| CN-101410385-B | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS LLC | 2011-08-24 | — | — | CN | disclosed |
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HIGH POINT PHARMACEUTICALS, LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HIGH POINT PHARMACEUTICALS, LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HIGH POINT PHARMACEUTICALS, LLC | 2010-11-25 | — | — | US | disclosed |
| CN-101410385-A | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-04-15 | — | — | CN | disclosed |
| EP-1999120-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | High Point Pharmaceuticals, LLC (US) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007110364-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HRH3, HRH2, HRH4 | NR1H2 553/4885NR1H3 619/4885MAPT 1467/4885 |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HRH3, HRH2, HRH4 | NR1H2 940/4885NR1H3 931/4885MAPT 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.